The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Ju-Hee Kang,Ju-Hee Kang,Magdalena Korecka,Michal J. Figurski,Jon B. Toledo,Kaj Blennow,Henrik Zetterberg,Henrik Zetterberg,Teresa Waligorska,Magdalena Brylska,Leona Fields,Nirali Shah,Holly Soares,Robert A. Dean,Hugo Vanderstichele,Ronald C. Petersen,Paul S. Aisen,Andrew J. Saykin,Michael W. Weiner,Michael W. Weiner,John Q. Trojanowski,Leslie M. Shaw +21 more
Reads0
Chats0
TLDR
In this paper, the authors describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ 1-42 ), t-tau, and p-Tau 181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD heterogeneity; progress in standardization; and new studies using ADNI biofluids.Abstract:
Introduction We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ 1–42 ), t-tau, and p-tau 181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. Methods Review publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ 1–42 , t-tau, and p-tau 181 data. Results CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. Discussion Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.read more
Citations
More filters
Journal ArticleDOI
Metabolic network failures in Alzheimer's disease: A biochemical road map
Jon B. Toledo,Jon B. Toledo,Matthias Arnold,Gabi Kastenmüller,Rui Chang,Rebecca Baillie,Xianlin Han,Madhav Thambisetty,Jessica D. Tenenbaum,Karsten Suhre,J. Will Thompson,Lisa St. John-Williams,Siamak Mahmoudiandehkordi,Daniel M. Rotroff,John Jack,Alison A. Motsinger-Reif,Shannon L. Risacher,Colette Blach,Joseph E. Lucas,Tyler Massaro,Gregory Louie,Hongjie Zhu,Guido Dallmann,Kristaps Klavins,Therese Koal,Sungeun Kim,Kwangsik Nho,Li Shen,Ramon Casanova,Sudhir Varma,Cristina Legido-Quigley,M. Arthur Moseley,Kuixi Zhu,Marc Henrion,Sven J. van der Lee,Amy C. Harms,Ayse Demirkan,Thomas Hankemeier,Thomas Hankemeier,Cornelia M. van Duijn,Cornelia M. van Duijn,John Q. Trojanowski,Leslie M. Shaw,Andrew J. Saykin,Michael W. Weiner,P. Murali Doraiswamy,Rima Kaddurah-Daouk +46 more
TL;DR: This article used metabolomics as a global biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance.
Journal ArticleDOI
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Jennifer Salazar,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski +15 more
TL;DR: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease clinical trials.
Journal ArticleDOI
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Piotr Lewczuk,Peter Riederer,Sid E. O'Bryant,Marcel M. Verbeek,Bruno Dubois,Pieter Jelle Visser,Kurt A. Jellinger,Sebastiaan Engelborghs,Alfredo Ramirez,Lucilla Parnetti,Clifford R. Jack,Charlotte E. Teunissen,Harald Hampel,Alberto Lleó,Frank Jessen,Lidia Glodzik,Mony J. de Leon,Anne M. Fagan,José Luis Molinuevo,Willemijn J. Jansen,Bengt Winblad,Leslie M. Shaw,Ulf Andreasson,Markus Otto,Brit Mollenhauer,Jens Wiltfang,Martin R Turner,Inga Zerr,Ron Handels,Alexander G. Thompson,Gunilla Johansson,Natalia Ermann,John Q. Trojanowski,Ilker Karaca,Holger Wagner,Patrick Oeckl,Linda J C van Waalwijk van Doorn,Maria Bjerke,Dimitrios Kapogiannis,H. Bea Kuiperij,Lucia Farotti,Yi Li,Brian A. Gordon,Stéphane Epelbaum,Stephanie J.B. Vos,Catharina J.M. Klijn,William E. Van Nostrand,Carolina Minguillon,Matthias Schmitz,Carla Gallo,Andrea Lopez Mato,Florence Thibaut,Simone Lista,Daniel Alcolea,Henrik Zetterberg,Kaj Blennow,Johannes Kornhuber +56 more
TL;DR: In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes the opportunity to extend and update the original paper.
Journal ArticleDOI
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski +14 more
TL;DR: In a recent review as discussed by the authors, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers.
Journal ArticleDOI
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Leslie M. Shaw,Jalayne J. Arias,Kaj Blennow,Doug R. Galasko,José Luis Molinuevo,Stephen Salloway,Suzanne E. Schindler,Maria C. Carrillo,James Hendrix,April Ross,Judit Illes,Courtney Ramus,Sheila Fifer +12 more
TL;DR: The Alzheimer's Association convened a multidisciplinary workgroup to develop appropriate use criteria to guide the safe and optimal use of the lumbar puncture procedure and cerebrospinal fluid testing for Alzheimer's disease pathology detection in the diagnostic process.
References
More filters
Journal ArticleDOI
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
TL;DR: The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available.
Journal ArticleDOI
Mild cognitive impairment as a diagnostic entity
TL;DR: It is suggested that the diagnosis of mild cognitive impairment can be made in a fashion similar to the clinical diagnoses of dementia and AD, and an algorithm is presented to assist the clinician in identifying subjects and subclassifying them into the various types of MCI.
Journal ArticleDOI
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
TL;DR: A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
Journal ArticleDOI
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.
Robert D. Terry,Eliezer Masliah,David P. Salmon,Nelson Butters,Richard DeTeresa,Robert Hill,Lawrence A. Hansen,Robert Katzman +7 more
TL;DR: Both linear regressions and multivariate analyses correlating three global neuropsychological tests with a number of structural and neurochemical measurements performed on a prospective series of patients with Alzheimer's disease and 9 neuropathologically normal subjects reveal very powerful correlations with all three psychological assays.
Journal ArticleDOI
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack,David S. Knopman,William J. Jagust,Leslie M. Shaw,Paul S. Aisen,Michael W. Weiner,Ronald C. Petersen,John Q. Trojanowski +7 more
TL;DR: This work proposes a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegnerative biomarker become abnormal later, and correlate with clinical symptom severity.
Related Papers (5)
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois,Bruno Dubois,Howard Feldman,Claudia Jacova,Harald Hampel,Harald Hampel,José Luis Molinuevo,Kaj Blennow,Steven T. DeKosky,Serge Gauthier,Dennis J. Selkoe,Randall J. Bateman,Stefano F. Cappa,Sebastian J. Crutch,Sebastiaan Engelborghs,Giovanni B. Frisoni,Nick C. Fox,Douglas Galasko,Marie-Odile Habert,Gregory A. Jicha,Agneta Nordberg,Florence Pasquier,Gil D. Rabinovici,Philippe Robert,Christopher C. Rowe,Stephen Salloway,Marie Sarazin,Stéphane Epelbaum,Stéphane Epelbaum,Leonardo Cruz de Souza,Leonardo Cruz de Souza,Leonardo Cruz de Souza,Bruno Vellas,Pieter Jelle Visser,Lon S. Schneider,Yaakov Stern,Philip Scheltens,Jeffrey L. Cummings +37 more